News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase I
Intra-Cellular Therapies, Inc. Announces Additional Results From Phase I/2 Clinical Trial For ITI-007 In Healthy Geriatric Subjects And Patients With Dementia 11/21/2014
Avaxia Biologics, Inc. Receives FDA Orphan Drug Designation For AVX-470 For The Treatment Of Pediatric Ulcerative Colitis 11/21/2014
Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus Pemetrexed And Cisplatin In Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 11/20/2014
Omni Bio Pharmaceutical Announces Presentation Of Phase 1/2 Clinical Data For AAT At American Heart Association Scientific Sessions 11/20/2014
Marina Biotech, Inc. (MRNA) Reports That Partner Mirna Therapeutics, Inc. Presented Interim Phase 1 Data On Its First-in-Class microRNA-34 Mimic 11/20/2014
Themis Bioscience’s Vaccine Against Chikungunya Successful In Phase 1 11/20/2014
DBV Technologies Initiates Phase I/2 Clinical Trial With Viaskin Milk For The Treatment Of Children With Cow's Milk Allergy 11/20/2014
St. Jude Children's Research Hospital Release: Gene Therapy Provides Safe, Long-Term Relief For Patients With Severe Hemophilia B 11/20/2014
Transition Therapeutics Inc. (TTH.TO) Announces Results From ELND005 Clinical Study In Adults With Down Syndrome 11/20/2014
Mirna Therapeutics, Inc. Presents Interim Phase 1 Data On First-In-Class Microrna-34 Mimic, MRX34, At The 26th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics 11/20/2014
Phase 1 Dose Escalation Data For Epizyme (EPZM) EZH2 Inhibitor EPZ-6438 (E7438) Shows Single Agent Activity In B-Cell Non-Hodgkin Lymphomas And Malignant Rhabdoid Tumor 11/20/2014
MabVax Therapeutics, Inc. And Memorial Sloan-Kettering Cancer Center Report On Potential Use Of Dual-Labeled Antibody To Detect And Guide Surgical Removal Of Pancreatic Cancer 11/19/2014
3-V Biosciences Announces Presentation Of First Human Clinical Data For Lead Oral FASN Inhibitor Candidate At European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research 2014 11/19/2014
Threshold Pharmaceuticals, Inc. (THLD) Announces Phase 1/2 Interim Data Signaling Activity Of TH-302 Plus Bevacizumab (Avastin(R)) In Patients With Glioblastoma 11/19/2014
OncoMed Pharmaceuticals, Inc. (OMED) Presents Biomarker-Focused Clinical Data From Phase 1a Trial Of Anti-Notch1 (OMP-52M51) In Oral Plenary Session At The 26th OncoMed Pharmaceuticals, Inc. (OMED)-European Organization for Research and Treatment of Cancer-National Cancer Institute Symposium 11/19/2014
Clovis Oncology (CLVS) Release: Interim Data From Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling And Durable Clinical Activity And Progression-Free Survival (PFS) In Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) 11/19/2014
Omni Bio Pharmaceutical Announces Phase 1/2 Clinical Data Of AAT In Myocardial Infarction At American Heart Association Scientific Session 11/19/2014
THERAVECTYS Provides Update On Its Phase 1/2 Lentiviral Vector-Based Therapeutic Vaccine Trial 11/19/2014
BerGenBio AS Receives Orphan-Drug Designation From FDA For BGB324 In The Treatment Of Acute Myeloid Leukaemia 11/19/2014
PTC Therapeutics, Inc. (PTCT) Release: Spinal Muscular Atrophy Program Enters Phase 1b/2a Trial In Patients With SMA 11/19/2014
Otologic Pharmaceutics Initiates Phase 1 Clinical Study Of HNPN-1010 For Hearing Disorders 11/19/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Publication Of Vosaroxin Phase 1b/2 AML Trial Results In Haematologica 11/19/2014
Cempra To Receive Biomedical Advanced Research and Development Authority (BARDA) Funding For 1b And Start-Up Of Phase 2/3 Solithromycin Pediatric Studies 11/19/2014
Agios Pharmaceuticals (AGIO) Announces Early Phase 1 Data Showing Clinical Activity Of AG-120 As A Single Agent In Advanced Acute Myeloid Leukemia (AML) 11/18/2014
The Lancet Neurology Publishes Prana’s Huntington Disease Trial 11/18/2014
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Data Show Idarucizumab* Restores Wound-Site Formation Of Fibrin, A Key Component Of Blood Clotting, In Healthy Volunteers Given Pradaxa (dabigatran etexilate mesylate) 11/18/2014
GlycoMimetics, Inc. (GLYC) Announces Positive Top-Line Results From Phase 1 Study Of GMI-1271 In Healthy Volunteers 11/18/2014
Arrowhead Research Corporation (ARWR) Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi Therapeutic ARC-AAT 11/18/2014
Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus Doxorubicin In HER2 Negative Breast Cancer 11/18/2014
Capricor Therapeutics, Inc. Announces Favorable ALLSTAR Phase I Safety Results 11/18/2014
Juno Therapeutics's JCAR015 Leukemia T Cell Therapy Granted Orphan Drug Designation By FDA 11/18/2014
Five Prime Therapeutics, Inc. (FPRX) Initiates Dosing Of Rheumatoid Arthritis Patients In Its Phase 1 Clinical Trial Of FPA008 11/17/2014
Relypsa, Inc. (RLYP) Announces Key Data Presented At American Society of Nephrology On Long-Term Chronic Treatment And Early Onset Of Action With Patiromer For Oral Suspension 11/17/2014
Exelixis, Inc. (EXEL) Announces Positive Preliminary Data From An Investigator-Sponsored Phase 1 Trial Of XL888 And Vemurafenib 11/17/2014
Allena Pharmaceuticals, Inc. Presents Phase 1 Data On ALLN-177 A American Society of Nephrology Kidney Week 2014 11/17/2014
Protalex, Inc. (PRTX) Announces Data From Phase 1b Trial Of PRTX-100 In Patients With Active Rheumatoid Arthritis Treated For Longer Duration Shows Safety And Reduction In Disease Activity 11/17/2014
Hemispherx Biopharma (HEB) Release: Ampligen(R) Blocks Critical Ebola Viral Disease (EVD) Protein Which Is Linked To High Mortality In Man 11/17/2014
DelMar Pharmaceuticals' Promising New Data Support The Potential Of VAL-083 To Meet Significant Unmet Medical Needs In The Treatment Of Glioblastoma Multiforme 11/17/2014
The Medicines Company (MDCO) Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters And Was Well-Tolerated In Healthy And Coronary Artery Disease (CAD) Patients 11/17/2014
CONRAD Launches First-Ever Multipurpose Vaginal Ring Clinical Trial 11/17/2014
Deciphera Pharmaceuticals Presents Data On Altiratinib (DCC-22701) That Demonstrated Inhibition Of Tumor Growth And Invasion In Bevacizumab Resistant Glioblastoma 11/17/2014
Anavex Life Sciences Corp. (AVXL.OB) Announces Positive Phase 1 Data For ANAVEX 2-73, Lead Candidate For The Treatment Of Alzheimer's 11/17/2014
AbbVie (ABBV) Presents Results From Study Of ABT-414 In Patients With Glioblastoma Multiforme At The 19th Annual Scientific Meeting And Education Day Of The Society For Neuro-Oncology 11/17/2014
NeuralStem Inc. NSI-189 Phase Ib Major Depression Disorder Neurogenic Biomarker Data Presented At The CNS Summit 11/17/2014
FlexPharma Presents Results From Three Human Clinical Studies 11/14/2014
Canadian Institutes Of Health Research Release: Canada Begins Ebola Vaccine Trial 11/14/2014
Five Prime Therapeutics, Inc. (FPRX) To Present Data From Healthy Volunteer Cohorts In Phase 1 Trial Of FPA008 At The 2014 American College of Rheumatology/ARHP Annual Scientific Meeting 11/14/2014
Cortice Biosciences Announces Initial Results From A Phase 1/2 Clinical Trial Evaluating TPI 287 For Treatment Of Recurrent Glioblastoma 11/14/2014
MaxiVAX SA Release: Swiss Biotech Starts Breakthrough Anti-Cancer Clinical Trial Based On Active Immunotherapy 11/13/2014
Cell Source's Megadose Drug Combination Receives Regulatory Approval In Italy To Commence Human Clinical Trials 11/13/2014
Oncoethix Starts Phase 1b Trials Of OTX015 In The Treatment Of Advanced Solid Tumors (OTX015_107) And Glioma (OTX015_108) 11/12/2014
Advaxis, Inc. Submits Investigational New Drug Application For Phase 1/2 Study Of ADXS-HPV And Medimmune's MEDI4736 For The Treatment Of HPV-Associated Cervical And Head & Neck Cancer 11/12/2014
Matinas BioPharma Commences Dosing In First Human Trial Of Lead Product Candidate MAT9001 11/12/2014
GliaCure's Lead Product, GC021109, Receives FDA Fast Track Designation 11/12/2014
ProMetic Life Sciences Inc. (PFSCF.PK)'s PBI-4050 Cleared To Commence Clinical Trials In Patients With Diabetic Kidney Disease 11/11/2014
Oncothyreon Inc. (ONTY) And Celldex Therapeutics, Inc. (CLDX) Announce Initiation Of Combination Immunotherapy Clinical Trial Of ONT-10 And Varlilumab 11/11/2014
Bionomics Limited (BNO.AX) To Progress BNC210 In Clinical Trials 11/11/2014
VaxInnate Corporation Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, Meets Phase 1 Seasonal Influenza Endpoints 11/11/2014
MA Startup SAGE Therapeutics' Drug For Rare Epilepsy Shows Promise In Small Study 11/10/2014
R-Tech Ueno: Completion Of A Phase I/II Clinical Study Of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) In The U.S. For The Treatment Of Severe Dry Eye 11/10/2014
Eagle Pharmaceuticals (EGRX) Reports Positive Outcomes From Clinical Trial Of Bendamustine HCl Product Delivered Via Low-Volume, Rapidly Infused Admixture 11/10/2014
Novira Therapeutics Announces Presentation Of Phase 1a Safety And Pharmacokinetic Data For NVR 3-778 11/10/2014
EnGeneIC Pty Ltd And Asbestos Diseases Research Institute Initiate Mesomir-1 Phase 1 Trial In Patients With Late Stage Mesothelioma 11/10/2014
NeuralStem Inc. Announces Publication Of Long Term Cell Survival From Phase I NSI-566 ALS Study In The Journal "Annals Of Clinical And Translational Neurology" 11/10/2014
Anavex Life Sciences Corp. (AVXL.OB) To Present Full Phase 1 Clinical Trial Data For ANAVEX 2-73 At CNS Summit 2014 Conference 11/10/2014
Galectin Therapeutics' Phase 1 Data Presented At American Association for Study of Liver Diseases Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development 11/10/2014
Novavax, Inc. (NVAX) Initiates Phase 1 Clinical Trial Of RSV F Vaccine In Pediatric Subjects 11/10/2014
SAGE Therapeutics Reports Positive Top-Line Phase 2 Data of SAGE-547 in Patients With Super-Refractory Status Epilepticus 11/10/2014
Seattle Children's Research Institute's Begins Recruiting Patients For Immunotherapy Research Trial For Neuroblastoma, One Of The Deadliest Forms Of Childhood Cancer 11/7/2014
Epizyme (EPZM) Reports Publication Of Preliminary Findings from Phase 1 Study Of DOT1L Inhibitor EPZ-5676 In American Society of Hematology Annual Meeting Abstract 11/6/2014
Cornerstone Pharmaceuticals, Inc. Announces Positive Phase I Data For CPI-613 In Relapsed Or Refractory AML Patients To Be Presented At 2014 American Society of Hematology Annual Meeting 11/6/2014
Perosphere Inc.’s Anticoagulant Reversal Agent Clinical Trial Results Published In The New England Journal of Medicine 11/6/2014
Merrimack Pharmaceuticals Inc. (MACK) Announces Initiation Of Phase 1 Clinical Study Of MM-398 For Brain Cancer 11/6/2014
BioLineRx Ltd. Announces Successful Final Results Of Phase 1/2 Study For Novel Celiac Treatment 11/5/2014
FDA Grants Orphan Drug Designation To Merrimack Pharmaceuticals Inc. (MACK)' MM-141 For The Treatment Of Pancreatic Cancer 11/5/2014
Que Oncology Announces Positive Phase 1 Results With Q-122 11/4/2014
Theravance Biopharma Announces Positive Results From Phase 1 Proof-of-Concept Study Of TD-6450, An NS5A Inhibitor To Treat Hepatitis C 11/4/2014
Edge Therapeutics Initiates Enrollment Of Third Cohort In Phase 1/2 NEWTON Study Of EG-1962 For Improvement Of Outcome After Ruptured Brain Aneurysm 11/4/2014
BerGenBio AS Announces First Patient Dosed in BGB324 AML Trial 11/4/2014
Ruthigen Announces First Patient Enrollment In The Phase 1/2 Human Clinical Trial Of RUT58-60, A Broad-Spectrum Anti-Infective Drug Candidate Designed For Prophylactic Use During Invasive Surgery 11/4/2014
Dyax Corp. (DYAX) Announces Expansion Of Phase 1b Clinical Trial For DX-2930 11/3/2014
Kolltan Pharmaceuticals Inc. Begins Phase 1b Cancer Study Evaluating KTN3379 In Combination With Multiple Targeted Therapies At Sarah Cannon Research Institute 11/3/2014
Suven Life Sciences Ltd Release: SUVN-G3031 For Cognition In Alzheimer’s Disease Commenced Phase 1 Clinical Trial In U.S.A. Under US-IND 123179 11/3/2014
MorEx Extends Phase I MTL-005 Radiation Enhancer Head & Neck Cancer Trial 11/3/2014
SAGE Therapeutics Release: First Evaluation Of SAGE-547 To Treat Super-Refractory Status Epilepticus In Children Published In Annals Of Neurology 11/3/2014
Xcovery Presents Phase 1 Results Of X-396 In ALK Positive NSCLC At The 2014 Multidisciplinary Symposium In Thoracic Oncology 10/31/2014
Kiadis Pharma's Lead Product ATIR™ Granted Orphan Drug Designation By European Medicines Agency For The Treatment Of Acute Myeloid Leukemia 10/30/2014
Advaxis, Inc.'s ADXS-Cher2 Immunotherapy Demonstrates T-Cell Immune Response In Data Analysis From Canine Osteosarcoma Study 10/30/2014
FDA Grants Fast Track Designation To Novavax, Inc. (NVAX)' H7N9 Influenza Virus-Like Particle Vaccine Candidate Adjuvanted With Matrix-M™ 10/30/2014
Hemispherx Biopharma (HEB) Reports New Evidence -- Based Potential Of Ampligen® Against Ebola Virus Disease (EVD) 10/30/2014
NovoCure Ltd. Enrolls First Patient In A Pilot Study Of Tumor Treating Fields (TTFields) Together With Paclitaxel For The Treatment Of Recurrent Ovarian Cancer 10/30/2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.)'s VC-01™ Investigational Stem Cell-Derived Islet Replacement Therapy Successfully Implanted Into First Patient 10/29/2014
Qu Biologics' Crohn's Disease Clinical Trial Completes Independent Safety Review 10/29/2014
FORUM Pharmaceuticals Presents FRM-0334 Studies At 9th International Conference On Frontotemporal Dementias 10/29/2014
Matinas BioPharma Receives Authorization From Health Canada To Initiate Human Clinical Study Of Lead Product Candidate MAT9001 10/29/2014
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Advances Clinical Study Of Mitochondrial Inhibitor ME-344 In Small Cell Lung And Ovarian Cancers 10/29/2014
Alnylam Pharmaceuticals (ALNY) And The Medicines Company (MDCO) Announce Filing Of A Clinical Trial Application To Initiate A Phase 1 Study For ALN-PCSsc, An Investigational, Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia 10/28/2014
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/28/2014
TxCell Achieves Positive Results For Col-Treg In A Model Of Autoimmune Uveitis 10/28/2014
Contract Research Organization WCCT Global Announces Involvement In H1N1 Oral Vaccine Development 10/28/2014
Osteros Biomedica Announce Initiation Of A Phase I Clinical Trial 10/28/2014
Merck & Co. (MRK) Scores Another Breakthrough For KEYTRUDA® 10/27/2014
Metanome, Inc. Selected As Metagenics Inc. Provider For Seres Health Clinical Trial 10/27/2014
Cytokinetics, Inc. (CYTK) Provides Development Program Update For Omecamtiv Mecarbil 10/27/2014
Arno Therapeutics Advances Phase I Trial Evaluating Onapristone In Progesterone Receptor Positive Tumors To Expansion Stage 10/27/2014
uniQure Release: AIPGENE Consortium Presents 1 Year Follow-Up Clinical Data From Acute Intermittent Porphyria Phase I Clinical Trial Using AAV5-PBGD Gene Therapy Candidate 10/27/2014
Aduro Biotech Presents Updated Interim Results From Phase 1b Clinical Trial In Mesothelioma At International Mesothelioma Interest Group Conference 10/24/2014
Synageva BioPharma (GEVA) Presents Sebelipase Alfa Data At The NASPGHAN Meeting 10/24/2014
Vitae Pharmaceuticals, Inc. (VTAE) Release: Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials Of BACE Inhibitor BI1181181/VTP-37948 In Alzheimer's Disease 10/24/2014
NIH Begins Early Human Clinical Trial Of VSV Ebola Vaccine 10/23/2014
Trinity Biotech (TRIB) Temporary Suspends Meritas Troponin Trials 10/23/2014
Clinical Trial To Evaluate Two Biothera Cancer Drugs For Advanced Pancreatic Cancer 10/23/2014
Vaxart, Inc. Accelerates Development Of Ebola Tablet Vaccine 10/23/2014
NeuralStem Inc. Alzheimer's Disease Animal Data Presented At The Congress Of Neurological Surgeons Annual Meeting 10/23/2014
Arno Therapeutics To Present Encouraging Data From Ongoing Phase 1/2 Trial Evaluating Onapristone In CRPC At 21st Annual PCF Scientific Retreat 10/23/2014
IntelliPharmaCeutics Reports Positive Results From A Series Of Phase I Clinical Trials Of Regabatin™ XR (Pregabalin Extended-Release) 10/23/2014
Johnson & Johnson (JNJ) Pledges $200 Million To Ebola, Will Begin Testing Vaccine In January 2015 10/22/2014
Phosplatin Therapeutics Announces First Patients Enrolled In Phase I First-in-Human Clinical Trial In Solid Tumors 10/22/2014
iCo Therapeutics Inc. Announces Advancement Of Oral Amphotericin B Program 10/22/2014
Atara Biotherapeutics (ATRA) Doses First Patient In Phase 1 Clinical Study Of STM 434, An Activin Inhibitor 10/22/2014
Athera Biotechnologies Initiates Phase I Trial With Its Fully Human Antibody PC-mAb 10/21/2014
Cornerstone Pharmaceuticals, Inc. Initiates Phase I Clinical Trial Of CPI-613 For The Treatment Of Hodgkin's Or T-Cell Non-Hodgkin's Lymphoma 10/21/2014
Generex Biotechnology Corporation (GNBT) Announces Publication Of Ebola Vaccine White Paper By Antigen Express, Inc. (GNBT) 10/21/2014
Agios Pharmaceuticals (AGIO) Announces Initiation Of A Phase 1/2 Clinical Trial Of AG-221 In Patients With Advanced Solid Tumors With An IDH2 Mutation 10/21/2014
ChemoCentryx, Inc. (CCXI)'s Orally Administered CCR9 Inhibitor, CCX507, Shown To Be Well Tolerated And Effective In CCR9 Blockade In Phase I Study 10/21/2014
Novartis AG (NVS)'s Leukemia Drug CTL01 Clears Cancer In 90 Percent Of Patients 10/20/2014
AgonOx’s OX40 Platform Being Utilized In MedImmune (AZN)’s Phase 1 OX40 Agonist Study 10/20/2014
R-Tech Ueno: Announcement Of Initiation Of The Phase I Clinical Trial For The Novel VAP-1 Inhibitor RTU-1096 10/20/2014
Milo Biotechnology's Follistatin Gene Therapy Increases Function In Becker Muscular Dystrophy Patients 10/20/2014
Galapagos NV (GLPG.BR) Discloses Novel Target And Presents Favorable Phase 1 Data For GLPG1205 At UEG Week 10/20/2014
Sarepta Therapeutics (SRPT) Announces Publication Of Ebola And Marburg Phase 1 Clinical Study Results; Contract With BioDefense Therapeutics 10/17/2014
GlobeImmune, Inc. (GBIM) Release: Updated Chordoma Data From Phase 1 Study Of GI-6301 Presented At 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting 10/17/2014
InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 10/17/2014
Ampio Pharmaceuticals, Inc. (AMPE) Announces Results Of The Open Label Portion Of The Multiple Intra-Articular Injections (MI) Study Of Ampion™ In Patients With Osteoarthritis Of The Knee At Week Twelve Of The Trial 10/17/2014
MediGene, Inc. Announces Publication In Cancer Immunology, Immunotherapy On DC Vaccine Development For A Phase 1/2 Trial In Acute Myeloid Leukemia 10/16/2014
Octreopharm Sciences Gets FDA Orphan Drug Designation For Management Of Neuroendocrine Tumors 10/16/2014
Stemline Therapeutics, Inc. (STML) Initiates SL-401 Trial In AML Patients In First Complete Response With Minimal Residual Disease, The Second SL-401 Trial Initiated In 2H14 10/16/2014
Advanced Cell Technology Announces Positive Results from Two Clinical Trials Published In Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells For The Treatment Of Macular Degeneration 10/15/2014
Sorrento Therapeutics, Inc. Release: Initial Pharmacokinetic Data From TRIBECA Study Support Potential For Bioequivalence Between Cynviloq And Albumin-Bound Paclitaxel 10/15/2014
Cellectar Biosciences  (NVLT) Announces Publication Of Findings Demonstrating Efficacy Of Its Phospholipid Ether Analog Platform In Detecting Colorectal Cancer 10/15/2014
Hanmi Pharmaceutical, Co., Ltd And Collaborative Partner Kinex Pharmaceuticals Announce Preliminary Results From A Phase I Clinical Study (HM-OTE-103) With Oratecan® In Patients With Advanced Cancer 10/15/2014
ActoGeniX Announces Positive Results From A Phase 1 Study Of AG014; Oral Capsule Administration Of An Anti-TNF-Alpha Antibody For The Treatment Of Inflammatory Bowel Disease 10/15/2014
Advaxis, Inc. Provides Clinical Update For Phase 1/2 Trial Of ADXS-HPV Immunotherapy Product Candidate In Anal Cancer 10/15/2014
Agios Pharmaceuticals (AGIO) Announces Initiation Of Four Expansion Cohorts In Phase 1 Study Of AG-221 10/15/2014
Advaxis, Inc.'s Lm-LLO Immunotherapy Data To Be Presented In Three Posters At The Society For Immunotherapy Of Cancer 29th Annual Meeting 10/14/2014
EU-Funded Consortium Led By immatics biotechnologies GmbH And BioNTech To Advance A Novel Class Of Fully Personalized Therapeutic Cancer Vaccines Into Clinical Trials For Brain Cancer 10/14/2014
Targeted Medical Pharma Releases Promising Trial Results For The Treatment Of Posttraumatic Stress Disorder 10/14/2014
Scancell Release: AGM Research And Development Update Highlights Progress In Both SCIB1 Clinical Trial And Moditope® Platform 10/14/2014
bluebird bio (BLUE) Announces First Patient With Sickle Cell Disease Transplanted With LentiGlobin Gene Therapy 10/14/2014
Acceleron Pharma Initiates Phase 1 Clinical Trial With Innovative Muscle Drug ACE-083 10/14/2014
Kineta Inc. Announces The Opening Of The First Psoriasis Clinical Trial Using Novel ShK-186 10/14/2014
Idera Pharmaceuticals, Inc. (IDRA) Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200 10/14/2014
Vaxart, Inc.’s Tablet Vaccine For H1N1 Influenza Generates Protective Immunity Equivalent To Injectable In Phase I Clinical Study 10/14/2014
Intra-Cellular Therapies, Inc.'s Dementia Drug Meets Phase 1/2 Goals 10/13/2014
Mali Health Workers Get Experimental GlaxoSmithKline (GSK) Ebola Vaccine 10/13/2014
Public Health Agency of Canada Release: Canadian Ebola Vaccine Trials Begin 10/13/2014
Concert Pharmaceuticals, Inc. (CNCE) Presents Positive Data From Multiple Dose Phase 1 Clinical Trial Of CTP-354, Lead Candidate For The Treatment Of Spasticity 10/13/2014
Bioheart, Inc. Announces Positive 12 Month Preliminary Data From Phase I Angel Trial 10/13/2014
Dynavax Technologies Corporation (DVAX) Initiates Phase 1/2 Study Of TLR-9 Agonist Immunotherapy In B-Cell Lymphoma 10/13/2014
Cytokinetics, Inc. (CYTK) Announces Development Program Update For CK-2127107 10/13/2014
CytoDyn Announces 100% Success With PRO 140 In Four-Week Monotherapy Clinical Trial 10/13/2014
Kite Pharma, Inc. (KITE) Announces Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells 10/13/2014
Momenta Pharmaceuticals, Inc. (MNTA) Announces Top-Line Part A Results From Phase 1/2 Trial Of Necuparanib In Patients With Pancreatic Cancer 10/10/2014
First Patient Treated In NeuralStem Inc. Phase I Spinal Cord Injury Stem Cell Trial Through The University of California, San Diego (UCSD) Sanford Stem Cell Clinical Center 10/9/2014
Regen BioPharma Submits Experimental Protocol To FDA For HemaXellerate Aplastic Anemia Trial 10/9/2014
Bone Therapeutics Extends ALLOB® Phase I/IIa Trial To Germany 10/9/2014
DelMar Pharmaceuticals Release: VAL-083 Demonstrates Promise As A Potential Treatment For Non-Small Cell Lung Cancer 10/9/2014
XOMA (US) LLC (XOMA) Launches XOMA 358 Clinical Development 10/9/2014
CytRx Corporation (CYTR) Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors 10/9/2014
Genocea Biosciences Presents Complete Phase 1/2a Data For HSV-2 Immunotherapy At IDWeek 10/8/2014
Ruthigen Initiates Phase 1/2 Clinical Trial Of RUT58-60 10/8/2014
VaxInnate Corporation Updates Plans To Advance Lead Vaccine Candidate, VAX2012Q In Elderly 10/8/2014
PharmaEngine, Inc. Will Join Nanobiotix' Pivotal Trial For NBTXR3 In Soft Tissue Sarcoma To Accelerate Its Development In Asia-Pacific 10/8/2014
OXiGENE (OXGN) Announces First Patient Enrolled In Phase 1b/2 Study Of Fosbretabulin Combined With Pazopanib In Patients With Advanced Recurrent Ovarian Cancer 10/8/2014
FDA Grants Clearance To Proceed With Clinical Study – New Drug Candidate From Vivolux Could Overcome Drug Resistance 10/7/2014
Cornerstone Pharmaceuticals, Inc.' CPI-613 Phase I Hematologic Malignancies Trial Data Published In Clinical Cancer Research 10/7/2014
Cavion And Yale University Announce First Patient Enrolled In Phase 1b Clinical Trial In Brain Cancer 10/7/2014
Bio-Path Holdings, Inc. (BPTH) Successfully Completes Cohort 6 Of Phase I Clinical Trial Evaluating Liposomal Grb-2 In Blood Cancers 10/7/2014
Debiopharm Group™ Announces Progress In Phase I Single And Multiple Ascending Dose Study Of Debio 1450, Its Potent Anti-Staphylococcal Agent 10/7/2014
Intra-Cellular Therapies, Inc. To Present Results From Phase 1/2 Clinical Trial For ITI-007 In Healthy Geriatric Subjects And Patients With Dementia At The American Neurological Association 139th Annual Meeting 10/7/2014
Ariad Pharmaceuticals, Inc. (ARIA)'s Lung Cancer Drug Wins Breakthrough Therapy Status 10/6/2014
Nitto Denko Corporation (XETRA: ND5.DE): New Anti-Fibrosis Drug With Molecular Targeting DDS Starts Phase-1B Dosing For Cirrhosis Patients 10/6/2014
Antibe Therapeutics Inc. Completes Single Ascending Dose Portion Of ATB-346 Phase I Program 10/6/2014
Prophylix To Commence Phase I/II Trials Of Naitgam (Anti-HPA-1a Immunoglobulin) For The Prevention Of Fetal And Neonatal Alloimmune Thrombocytopenia 10/2/2014
FDA Grants Fast Track Designation To NKT Therapeutics Inc.' NKTT120 For The Treatment Of Sickle Cell Disease 10/2/2014
Heat Biologics Completes Enrollment Of Phase 1 Clinical Trial Of Vesigenurtacel-L For The Treatment Of Bladder Cancer Required To Advance To Phase 2 10/2/2014
Curis, Inc. (CRIS) Announces CUDC-907 Development Program Advancements 10/2/2014
Innate Pharma (IPH.PA ) : Initiation Of A Phase I Clinical Trial Of Lirilumab In Combination With Elotuzumab 10/1/2014
Merck & Co. (MRK)'s Keytruda Shows Positive Signs In Bladder Cancer Trial 9/30/2014
Celldex Therapeutics, Inc. (CLDX) Announces Publication Of Glembatumumab Vedotin Phase 1/2 Studies In The Journal Of Clinical Oncology 9/30/2014
Helix Biopharma (CC:HBP) Reports On Interim Review Of The Polish L-DOS47 Monotherapy Study In Non-Small Cell Lung Cancer 9/30/2014
Sarepta Therapeutics (SRPT) Announces Favorable Safety Results From Phase I Clinical Study Of Influenza Drug Candidate 9/30/2014
Merck & Co. (MRK)'s Keytruda Extends Immune System Fight To Stomach Cancer 9/29/2014
CEL-SCI (CVM) & U.S. Navy Administer Multikine To First Volunteer Patient In Phase I Clinical Trial For Treatment Of Anal Warts In HIV/HPV Co-Infected Patients 9/29/2014
Helix Biopharma (CC:HBP) Initiates Enrollment For Tenth Cohort In Polish Phase I/II Clinical Study Of Its Lung Cancer Drug Candidate L-DOS47 9/29/2014
AstraZeneca PLC (AZN) Release: AZD9291 Shows Durable Clinical Response In Patients With Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer At The ESMO 2014 Congress 9/29/2014
Ignyta (RXDX) Announces Interim Data From RXDX-101 Phase I Clinical Trial At 2014 ESMO Congress 9/29/2014
Ariad Pharmaceuticals, Inc. (ARIA) Presents Updated Clinical Data On AP26113 In Patients With ALK+ Non-Small Cell Lung Cancer 9/29/2014
Cytogel Pharma (Cytogel) Announces Presentation At The 8th Annual Pain And Migraine Therapeutics Summit In Boston On September 24, 2014, Novel Mu Opioid Mechanisms For The Potent Analgesic Cyt-1010 Distinguish It From Morphine 9/29/2014
OncoMed Pharmaceuticals, Inc. (OMED)'s Demcizumab Phase 1b Clinical Trials Show Encouraging Safety And Anti-Tumor Activity At ESMO 9/29/2014



//-->